Evidence map›Paper›PMID 30689715›Full record

ArticleBioinformatics (Oxford, England)2019

Inferring clonal heterogeneity in cancer using SNP arrays and whole genome sequencing.

Mark R Zucker, Lynne V Abruzzo, Carmen D Herling, Lynn L Barron, Michael J Keating, Zachary B Abrams, Nyla Heerema, Kevin R Coombes

Erratum issuedAbstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Cell lineage tracing: Methods, applications, and challenges.Quantitative biology (Beijing, China) · 2025
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Mark R ZuckerDepartment of Biomedical Informatics, Wexner Medical Center, The Ohio State University, Columbus, OH, USA.
Lynne V AbruzzoDepartment of Pathology, Wexner Medical Center, The Ohio State University, Columbus, OH, USA.
Carmen D HerlingDepartment I of Internal Medicine, CIO Köln-Bonn, and CECAD, University of Cologne, Cologne, Germany.
Lynn L BarronDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Texas, MD, USA.
Michael J KeatingDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Texas, MD, USA.
Zachary B AbramsDepartment of Biomedical Informatics, Wexner Medical Center, The Ohio State University, Columbus, OH, USA.
Nyla HeeremaDepartment of Pathology, Wexner Medical Center, The Ohio State University, Columbus, OH, USA.
Kevin R CoombesDepartment of Biomedical Informatics, Wexner Medical Center, The Ohio State University, Columbus, OH, USA.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Protein-coding and non-coding RNA biomarkers for early detection of CLLR01CA182905 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ABRUZZO, LYNNE V., CALIN, GEORGE A. · 2014 to 2018
$2.9M
The OSU Clinical and Translational Research Informatics Training Program (CTRIP)T15LM011270 · NLM · OHIO STATE UNIVERSITY · PI COOMBES, KEVIN ROBERT, JANIES, DANIEL A. · 2012 to 2016
$2.2M
NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA182905NLM NIH HHS T15 LM011270
6 · The paper itself

Abstract

motivationClonal heterogeneity is common in many types of cancer, including chronic lymphocytic leukemia (CLL). Previous research suggests that the presence of multiple distinct cancer clones is associated with clinical outcome. Detection of clonal heterogeneity from high throughput data, such as sequencing or single nucleotide polymorphism (SNP) array data, is important for gaining a better understanding of cancer and may improve prediction of clinical outcome or response to treatment. Here, we present a new method, CloneSeeker, for inferring clinical heterogeneity from sequencing data, SNP array data, or both.

resultsWe generated simulated SNP array and sequencing data and applied CloneSeeker along with two other methods. We demonstrate that CloneSeeker is more accurate than existing algorithms at determining the number of clones, distribution of cancer cells among clones, and mutation and/or copy numbers belonging to each clone. Next, we applied CloneSeeker to SNP array data from samples of 258 previously untreated CLL patients to gain a better understanding of the characteristics of CLL tumors and to elucidate the relationship between clonal heterogeneity and clinical outcome. We found that a significant majority of CLL patients appear to have multiple clones distinguished by copy number alterations alone. We also found that the presence of multiple clones corresponded with significantly worse survival among CLL patients. These findings may prove useful for improving the accuracy of prognosis and design of treatment strategies. AVAILABILITY AND IMPLEMENTATION: Code available on R-Forge: https://r-forge.r-project.org/projects/CloneSeeker/. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellPolymorphism, Single NucleotideWhole Genome SequencingAlgorithmsDNA Copy Number VariationsFemaleHigh-Throughput Nucleotide SequencingHumansMale

Identifiers

PMID30689715
PMCPMC6736450

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.